NCT06699498View on ClinicalTrials.gov

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2027

Conditions
Head and Neck Squamous Cell CarcinomaNeoadjuvant TherapyPD-L1Anlotinib
Interventions
DRUG

Benmelstobart

1200mg, D1, IV,q3w

DRUG

Anlotinib

10mg，D1-14，po，q3w

DRUG

Cisplatin

60mg/m2， D1， IV，q3w

DRUG

Paclitaxel for Injection （Albumin Bound）

260mg/m2，IVgtt ，D1，q3w

Trial Locations (1)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER